Brought to you by 
Editas gets CRISPR/Cas9, TALENS technology from Broad/Harvard/MIT
15 Jun 2018
Executive Summary
The Broad Institute, Harvard University, and Massachusetts Institute of Technology granted Editas Medicine Inc. an exclusive global license to their CRISPR/Cas9 and TALENS genome editing tools, which the biotech will use in the prevention and treatment of human disease. The transaction also includes a protein-based drug delivery system.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Editas gets CRISPR/Cas9, TALENS technology from Broad/Harvard/MIT
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice